Cancer Heterogeneity and Plasticity
@CHP_journal
Followers
28
Following
59
Media
31
Statuses
54
ISSN 2818-7792 Free Publication in 2025
Joined November 2024
🎉 We’re thrilled to celebrate the 1-year anniversary of Cancer Heterogeneity and Plasticity (CHP) ! 🧬The only scientific journal dedicated to understanding cancer cell states, plasticity, and tumor microenvironment. 👇See what we’ve accomplished in Year 1
2
2
3
🙌 Special thanks to conference organizers @stephaniema912 @hku_med, @JustinLathia @ClevelandClinic, and @VivianLiLab @TheCrick for leading the Cellular Plasticity in Cancer @FASEBorg SRC — a truly global effort connecting scientists across disciplines and continents. #CPCSRC
0
0
2
🔍 Key Meeting Themes: • Oncofetal reprogramming in the TME • EMT-induced stemness & hybrid states • Organoid & single-cell modeling • Metabolic rewiring & immune evasion • Novel therapies targeting stem-like states Co-authored by 18 global leaders including Behrens,
1
0
1
🎉 Conference Highlights Published! The inaugural FASEB Science Research Conference (SRC) on Cellular Plasticity in Cancer—held in Hong Kong (May 2025)—is now featured in CHP Journal! Leading experts share how cancer cell plasticity drives heterogeneity, stemness & therapy
pivotscipub.com
Advancing Cancer Biology: Highlights from the 2025 FASEB SRC on Cellular Plasticity in Cancer
1
1
2
This review from Drs. Duhon and McLean dissects how tumor heterogeneity—spatial, temporal, and microenvironmental—impacts the efficacy and resistance of antibody-drug conjugates (ADCs). Key insights: 🔹 7 FDA-approved ADCs now in solid tumors 🔹 Targeting strategies evolving
0
1
2
🔥 Hot off the press in CHP! “Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates” by Ashley A. Duhon, MD, PhD (@ashleyaduhon) & Karen McLean, MD, PhD (@karenmcl13) from @RoswellPark. ADCs are reshaping solid tumor therapy—but
pivotscipub.com
Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates
1
1
2
Continuing highlights from Li et al. (2025) — Figures 5–6 show: 📦 Exosome-mediated CSC–TME signaling 🌫️ Hypoxia + endothelial signals → Notch, Wnt, STAT3 activation & stemness marker upregulation
0
1
2
Key highlights from Li et al. (2025): CSC–TME networking drives progression & therapy resistance. 🔹 CSCs recruit & polarize TAMs & MDSCs 🔹 CAFs & MSCs reinforce stemness & EMT 🔹 Exosomes deliver pro-tumoral cargo 🔹 Endothelial cells + hypoxia fuel plasticity 🔹
1
1
2
🔥 Just published in CHP! “Regulation of Cancer Stem Cells in the Tumor Microenvironment” A comprehensive review by Aidan Li, Na Li, Yajing Yang, Linzhou Wang, Jessica Miao & Qi-En Wang (Ohio State Univ, Colleage of Medicine, Dpet of Radiation Oncology @OhioStateMed; OSU
pivotscipub.com
Regulation of Cancer Stem Cells in the Tumor Microenvironment
1
1
2
🔥 New in CHP! “Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response” By Erik S. Knudsen, Thomas N. O’Connor & Agnieszka K. Witkiewicz @RoswellPark Cancer cells bend cell-cycle rules—switching CDK/Cyclin drivers to thrive & resist
0
1
3
🩺 Clinical takeaways: Table 1: Diagnostic tools for nonbone mPCa — PSMA PET, FDG PET, DLL3 imaging, tissue & liquid biopsies. Table 2: Treatment strategies across mCSPC, mCRPC, NEPC, DNPC & novel therapies. OA Review: https://t.co/Yp4MAon3TD
0
0
1
🔥 Fresh out of the oven in CHP! Nonbone Metastasis in Prostate Cancer: Diagnosis & Treatment New review by Genyu Du, Penghui Xu, Helen He Zhu & Na Jing(Ren Ji Hosp, Shanghai Cancer Inst, SJTU Med). Focus: liver mets, tumor microenvironment, diagnostic strategies & novel
1
0
2
🔎 Mechanisms & therapies: Figure 2: Tumor factors activate STAT3 & Notch in astrocytes → pro-metastatic reprogramming. Figure 3: Parallels CAFs & astrocytes in ECM remodeling, immune modulation, paracrine signaling. Table 1: Drugs targeting astrocyte–tumor crosstalk (Cx43
0
0
2
✨ Spotlight review in CHP! Astrocyte plasticity shapes brain metastasis progression through tumor–astrocyte crosstalk By Rupleen Kaur (@rupleenkaur), Dr. Andrew Dhawan (@andrewdhawan) from @cwru & @ClevelandClinic, and Nalin Gupta (@WashUBME). OA Review:
1
2
4
📈 Clinical & translational insights: F5: Prognostic impact—high DIAPH3 linked to poor survival T1: Roles across cancers (oncogenic, context-specific) T2: Small-molecule modulators (e.g., SMIFH2 inhibitor, IMM-01/02 agonists)
0
1
3
📊 Figures 1–4 spotlight: F1: DIAPH3 isoforms & formin domains F2: Actin, microtubule, nuclear roles F3: TCGA pan-cancer landscape F4: Oncogenic signaling & TME remodeling
1
0
2
✨ Spotlight review in CHP! DIAPH3: A Cytoskeleton Remodeler Driving Cancer Progression & a Potential Therapeutic Target By Jiangling Xiong & Lanxin Hu (co-first authors), with Prof. Dingxiao Zhang & team (Hunan Univ @hunanuniv), Prof. Yang Mei (Hunan Univ), Prof. Dinglan Wu
1
1
2
🔬 Welcome Dr. Ping Mu (@PingMu_PhD) to CHP Journal as Associate Editor! At Yale School of Medicine, Dr. Mu leads transformative research into prostate cancer therapy resistance, immune modulation & spatial heterogeneity. 🧠 Translational platforms include AI-guided precision
0
1
6
🔥 Hot off the press! 🧬 Can senescent tumor cells relapse? In this new #Perspective, Dr. James Jackson (@TulaneMedicine) dissects the three barriers that senescent cancer cells must overcome to drive relapse: > Intrinsic death >> Immune escape >>> Cell cycle re-entry 📖 Read:
0
0
2
I am thrilled to be joining the Editorial Board of Cancer Heterogeneity and Plasticity.
🔬 Welcome Dr. Ping Mu (@PingMu_PhD) to CHP Journal as Associate Editor! At Yale School of Medicine, Dr. Mu leads transformative research into prostate cancer therapy resistance, immune modulation & spatial heterogeneity. 🧠 Translational platforms include AI-guided precision
0
1
9
@mishabeltran 💫 We also proudly congratulate Dr. Suling Liu on her promotion to Associate Editor at CHP Journal! As Professor at Zhejiang University School of Medicine, Dr. Liu leads groundbreaking research in breast cancer stem cells, therapy resistance, and immune regulation. 🎯 Her lab
0
0
2